HAYWARD, California — March 9, 2026
Medical technology innovator Pulse Biosciences, Inc. has reported encouraging clinical outcomes from the first-in-human study evaluating its nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of benign thyroid nodules using Nanosecond Pulsed Field Ablation (nsPFA™) technology. The study demonstrated durable and sustained volume reduction of thyroid nodules, with an average reduction of 74% observed between 15 and 22 months after treatment, highlighting the potential of this non-thermal bioelectric therapy to transform thyroid nodule management. These clinical results were presented at the North American Society for Interventional Thyroidology 2026 meeting in Portland, Oregon, providing early but promising evidence that the technology may offer a safe and effective alternative to conventional surgical or thermal ablation procedures.
Durable Clinical Results Demonstrate Long-Term Effectiveness
The extended follow-up analysis included 21 patients who were monitored for 15 to 22 months after treatment, allowing researchers to evaluate the long-term durability of the ablation results. Investigators reported significant and sustained reduction in nodule volume, with the average 74% decrease maintained throughout the follow-up period. Importantly, researchers observed no evidence of nodule regrowth during the monitoring period, indicating that the treatment effect remained stable over time.
The study also highlighted high levels of patient satisfaction, which is a critical factor in evaluating treatment success for benign thyroid conditions that often affect appearance and quality of life. According to patient-reported outcomes, 100% of participants reported being highly satisfied with their cosmetic results, while 95% expressed high overall satisfaction with the treatment experience. These findings suggest that the minimally invasive nature of the procedure may provide both clinical effectiveness and strong patient acceptance.
Researchers also reported no serious adverse events and no intranodular fibrosis detected during ultrasound evaluations, further supporting the safety profile of the technology. These outcomes are particularly significant because many traditional treatments for benign thyroid nodules involve surgical intervention or thermal ablation techniques that may carry risks such as scarring, tissue damage, or prolonged recovery times.
Advertisement
Nanosecond Pulsed Field Ablation Enables Non-Thermal Tissue Treatment
The promising results are attributed to Pulse Biosciences’ proprietary nPulse technology, which delivers extremely short bursts of electrical energy to targeted cells through Nanosecond Pulsed Field Ablation (nsPFA). Unlike thermal ablation methods that rely on heat or cold to destroy tissue, nsPFA technology uses ultra-short electrical pulses to selectively disrupt cellular membranes, effectively eliminating targeted cells while preserving surrounding non-cellular structures such as connective tissue and blood vessels.
This non-thermal bioelectric approach allows precise tissue targeting, reducing the likelihood of collateral damage to nearby healthy structures. In thyroid procedures, where delicate anatomical structures such as nerves and blood vessels are located near the treatment area, this precision is particularly important. The ability of nsPFA energy to clear cells without generating thermal injury may therefore offer a safer and more controlled treatment option for benign thyroid nodules.
Clinical investigators noted that the unique characteristics of nsPFA energy—including rapid particle flow and high voltage pressure applied over extremely short time intervals—distinguish it from other pulse field ablation techniques currently under development. These characteristics may contribute to the durable tissue response observed in the study.
Advancing Bioelectric Medicine and Future Clinical Research
Pulse Biosciences is positioning its nPulse technology as a platform for bioelectric medicine, a rapidly emerging field focused on using electrical energy to treat disease at the cellular level. While the thyroid nodule feasibility study represents an early clinical investigation, the company believes the results provide a strong foundation for further research and potential clinical applications.
Company leadership emphasized that the long-term follow-up results represent the first evidence demonstrating sustained tissue response using nsPFA energy for benign thyroid nodules, reinforcing the potential for the technology to become an innovative treatment paradigm. In addition to thyroid applications, Pulse Biosciences is actively exploring the use of nsPFA technology in atrial fibrillation treatment and surgical soft-tissue ablation, areas where non-thermal ablation may offer advantages over conventional energy-based therapies.
The company plans to continue expanding its clinical evidence base and will provide further updates on its non-cardiac nsPFA development strategy later in 2026. As interest grows in minimally invasive and precision-guided treatments, bioelectric technologies like nPulse may represent a new frontier in therapeutic innovation.
With these promising early clinical results, Pulse Biosciences is advancing the development of a technology platform that could potentially improve patient outcomes, reduce procedure complexity, and expand treatment options for individuals with benign thyroid nodules and other medical conditions. Continued research and larger clinical studies will be essential to confirm these findings and determine the full clinical potential of nsPFA-based therapies.
z
Source: Pulse Biosciences press release
